LAVA Therapeutics N.V.
LVTX
$1.52
$0.010.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.58% | 1.73% | 39.88% | 45.23% | 40.57% |
| Total Depreciation and Amortization | -60.07% | -50.56% | -58.17% | -86.47% | -74.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -247.90% | -204.58% | -63.91% | -33.56% | -56.31% |
| Change in Net Operating Assets | 46.08% | 114.04% | 205.11% | -113.86% | -119.23% |
| Cash from Operations | -26.80% | 8.83% | 52.61% | -507.62% | -310,344.44% |
| Capital Expenditure | -228.57% | 100.00% | 96.85% | 97.59% | 99.27% |
| Sale of Property, Plant, and Equipment | 203.26% | -101.12% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 196.98% | 210.17% | 173.41% | 40.01% | -317.22% |
| Cash from Investing | 198.37% | 209.43% | 170.74% | 45.11% | -336.64% |
| Total Debt Issued | -10.21% | -121.37% | -- | -353.92% | -153.90% |
| Total Debt Repaid | -164.83% | -248.13% | -- | 173.19% | 168.58% |
| Issuance of Common Stock | -91.67% | 125.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -306.47% | -631.43% | -- | 152.13% | 200.36% |
| Foreign Exchange rate Adjustments | 951.06% | 100.00% | -212.71% | -88.75% | -122.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.42% | 93.88% | 83.57% | -2,038.95% | -547.36% |